Diligence memo · auto-generated · as of July 2, 2026
Araceli Biosciences Inc.
Araceli Biosciences Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Araceli Biosciences Inc. operates in Biotech / Pharma, based in TIGARD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Araceli Biosciences Inc. has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2024-12-31.
Most recent recorded round closed around 2024-12-31.
Valuation (modeled)modeled
Provath models Araceli Biosciences Inc. at approximately $50M (range $14M–$97M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.30× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era. Within the normal band (130% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 18 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 4.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.